<DOC>
	<DOCNO>NCT00109408</DOCNO>
	<brief_summary>This 2 arm study assess safety efficacy tocilizumab monotherapy versus methotrexate patient active rheumatoid arthritis ( RA ) . Patients randomize receive tocilizumab 8mg/kg iv every 4 week plus placebo po weekly , methotrexate 7.5-20mg po weekly plus placebo iv every 4 week . The anticipated time study treatment 3-12 month target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy Tocilizumab Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient least 18 year age active RA least 3 month ; patient reproductive potential must use reliable method contraception . major surgery ( include joint surgery ) within 8 week enter study plan major surgery within 6 month enter study ; treatment methotrexate ( MTX ) within 6 month enter study ; patient stop previous MTX treatment due toxicity lack response ; woman pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>